Silver Spring, Maryland 20910

  • Diarrhea


This study is an open-labeled dose escalating trial in which a total of 32 subjects will receive one of four intranasal rFla-MBP vaccine doses.

Study summary:

This is an open labeled dose escalating trial in which a total of 32 subjects will receive one of four intranasal rFla-MBP vaccine doses according to the following chart: Group / N* / rFla-MBP A / 8/ 25 micrograms B / 8/ 125 micrograms C / 8/ 625 micrograms D / 8/ 1000 micrograms * minimum of 6 volunteers per group An interval no less than 60 days following the first dose will separate the first dose of each volunteer group receiving different rFla-MBP doses. All volunteers will receive three immunizations. The first dosing time point is Day 0, the second is Day 14 (+/- 1 day), the third is day 28 (+/- 2 days). Blood and stool specimens will be collected at intervals to examine systemic and mucosal vaccine antigen-specific immune responses. Vaccine safety will be actively monitored during vaccination and for 28 days following the third vaccine dose.


Inclusion Criteria: - Healthy adult - 70% accuracy on comprehension test - Availability for required visits and telephone follow up Exclusion Criteria: - Pregnancy or breastfeeding - Chronic health problems - Abnormalities found on physical examination - Use of immunosuppressive drugs, such as corticosteroids or chemotherapy - Positive blood test for HIV-1, hepatits B surface antigen (HBsAG) or hepatitis C virus (HCV) - Abnormalities found on basic laboratory screening - Prior exposure to Campylobacter - Current smoker - Chronic sinusitis or seasonal rhinitis



Primary Contact:

Principal Investigator
David Tribble, MD, DrPH
Naval Medical Research Center

Backup Contact:


Location Contact:

Silver Spring, Maryland 20910
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.